A phase IIa study of rhLTα-Da in combination with cisplatin and fluorouracil for patients with metastatic esophageal squamous cell carcinoma or gastric adenocarcinoma.

about

Efficacy and safety of recombinant human lymphotoxin-α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trial.

P2860

Q48237143-D907802A-F566-4EB1-9431-12DCC325D5C3

P2860

A phase IIa study of rhLTα-Da in combination with cisplatin and fluorouracil for patients with metastatic esophageal squamous cell carcinoma or gastric adenocarcinoma.

Item

http://www.wikidata.org/entity/Q40085069

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

A phase IIa study of rhLTα-Da ...... oma or gastric adenocarcinoma.

@en

type

Item

label

A phase IIa study of rhLTα-Da ...... oma or gastric adenocarcinoma.

@en

prefLabel

A phase IIa study of rhLTα-Da ...... oma or gastric adenocarcinoma.

@en

P1476

A phase IIa study of rhLTα-Da ...... oma or gastric adenocarcinoma.

@en

P2093

Feng-Hua Wang

http://www.w3.org/2001/XMLSchema#string

Feng-Zhan Qin

http://www.w3.org/2001/XMLSchema#string

Jian-Hua Chen

http://www.w3.org/2001/XMLSchema#string

Wen-Qi Jiang

http://www.w3.org/2001/XMLSchema#string

Yun Wang

http://www.w3.org/2001/XMLSchema#string

Zhen-Dong Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface

Association of the Asp312Asn and Lys751Gln polymorphisms in the XPD gene with the risk of non-Hodgkin's lymphoma: evidence from a meta-analysis

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.

Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism.

Creation of lysine-deficient mutant lymphotoxin-alpha with receptor selectivity by using a phage display system.

Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy.

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.

Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.

P2888

s12032-016-0846-5

P304

125

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12032-016-0846-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yu-Hong Li

P577

2016-10-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1048558654

http://www.w3.org/2001/XMLSchema#string

P698

27743200

http://www.w3.org/2001/XMLSchema#string

A phase IIa study of rhLTα-Da in combination with cisplatin and fluorouracil for patients with metastatic esophageal squamous cell carcinoma or gastric adenocarcinoma.

about

P2860

P2860

A phase IIa study of rhLTα-Da in combination with cisplatin and fluorouracil for patients with metastatic esophageal squamous cell carcinoma or gastric adenocarcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698